At present, curative therapy for CML is limited primarily to the small fraction of patients with stable phase disease who are eligible for an HLA- matched bone marrow transplant. There has recently been renewed interest in developing immunotherapies for cancer because of a number of discoveries in basic immunology. These discoveries include major advances in the understanding of antigen presentation, T cell regulation, and the mechanisms of tolerance or anergy. In theory, many cancers have potential tumor antigens in the form of mutations in dominant oncogenes, viral oncogenes, or other neoantigens. CML is an example, where the p210 BCR/ABL oncogene itself is a possible tumor antigen, as are mutations in other proto-oncogenes such as p53 and p21 ras which are commonly observed in advanced forms of the disease. It is evident that most or all patients with CML generate either no immune response to athe tumor or an ineffective immune response. The immune response to leukemia cells may be impaired because leukemic antigens are typically presented to T cells in such a manner as to force the development of tolerance rather than active immunity. Tolerance is believed to be caused by the presentation of antigen to T cells in the absence of a costimulatory signal through CD28. The goals of this project will be to develop animal models to explore the immune response to a leukemia antigen (p210BCR/ABL), to investigate ways of manipulating the immune response in vivo as a correlate to in vitro studies with human cells conducted in other projects, to find novel ways to induce an effective immune response in leukemic animal which could lead to clinical trials, and to generate new animal models of CML which more accurately reflect human disease. This models produced by this project will also be used by investigators in other projects to test new concepts about tolerance or techniques for altering immune responses to tumors. Over the long term, this project should contribute tot he development of novel therapies for human leukemias and lymphomas.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA066996-01A1
Application #
5209408
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
1996
Total Cost
Indirect Cost
Weinberg, Olga K; Gibson, Christopher J; Blonquist, Traci M et al. (2018) Association of mutations with morphological dysplasia in de novo acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities. Haematologica 103:626-633
Hoshii, Takayuki; Cifani, Paolo; Feng, Zhaohui et al. (2018) A Non-catalytic Function of SETD1A Regulates Cyclin K and the DNA Damage Response. Cell 172:1007-1021.e17
Gooptu, Mahasweta; Kim, Haesook T; Chen, Yi-Bin et al. (2018) Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial. Biol Blood Marrow Transplant 24:2216-2223
Gutierrez-Martinez, Paula; Hogdal, Leah; Nagai, Manavi et al. (2018) Diminished apoptotic priming and ATM signalling confer a survival advantage onto aged haematopoietic stem cells in response to DNA damage. Nat Cell Biol 20:413-421
Nabet, Behnam; Roberts, Justin M; Buckley, Dennis L et al. (2018) The dTAG system for immediate and target-specific protein degradation. Nat Chem Biol 14:431-441
Kleppe, Maria; Koche, Richard; Zou, Lihua et al. (2018) Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. Cancer Cell 33:29-43.e7
List, Alan; Ebert, Benjamin L; Fenaux, Pierre (2018) A decade of progress in myelodysplastic syndrome with chromosome 5q deletion. Leukemia 32:1493-1499
Ebert, Benjamin L; Krönke, Jan (2018) Inhibition of Casein Kinase 1 Alpha in Acute Myeloid Leukemia. N Engl J Med 379:1873-1874
Sellar, Rob S; Jaiswal, Siddhartha; Ebert, Benjamin L (2018) Predicting progression to AML. Nat Med 24:904-906
Hshieh, Tammy T; Jung, Wooram F; Grande, Laura J et al. (2018) Prevalence of Cognitive Impairment and Association With Survival Among Older Patients With Hematologic Cancers. JAMA Oncol 4:686-693

Showing the most recent 10 out of 376 publications